- Home
- PPBT vs POAI Comparison
PPBT vs POAI Comparison
Compare PPBT & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- POAI
- Stock Information
- Founded
- PPBT 2010
- POAI 2002
- Country
- PPBT Israel
- POAI United States
- Employees
- PPBT N/A
- POAI N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- POAI Industrial Specialties
- Sector
- PPBT Health Care
- POAI Health Care
- Exchange
- PPBT Nasdaq
- POAI Nasdaq
- Market Cap
- PPBT 8.7M
- POAI 9.7M
- IPO Year
- PPBT N/A
- POAI N/A
- Fundamental
- Price
- PPBT $2.70
- POAI $1.12
- Analyst Decision
- PPBT Strong Buy
- POAI Hold
- Analyst Count
- PPBT 1
- POAI 1
- Target Price
- PPBT $33.00
- POAI N/A
- AVG Volume (30 Days)
- PPBT 16.9K
- POAI 418.3K
- Earning Date
- PPBT 03-10-2025
- POAI 03-27-2025
- Dividend Yield
- PPBT N/A
- POAI N/A
- EPS Growth
- PPBT N/A
- POAI N/A
- EPS
- PPBT N/A
- POAI N/A
- Revenue
- PPBT N/A
- POAI $1,484,223.00
- Revenue This Year
- PPBT N/A
- POAI N/A
- Revenue Next Year
- PPBT N/A
- POAI $569.48
- P/E Ratio
- PPBT N/A
- POAI N/A
- Revenue Growth
- PPBT N/A
- POAI N/A
- 52 Week Low
- PPBT $2.00
- POAI $0.55
- 52 Week High
- PPBT $20.60
- POAI $3.11
- Technical
- Relative Strength Index (RSI)
- PPBT 36.04
- POAI 40.72
- Support Level
- PPBT $2.61
- POAI $1.02
- Resistance Level
- PPBT $3.00
- POAI $1.15
- Average True Range (ATR)
- PPBT 0.21
- POAI 0.09
- MACD
- PPBT -0.01
- POAI -0.04
- Stochastic Oscillator
- PPBT 5.29
- POAI 22.92
Stock Price Comparison Chart: PPBT vs POAI
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.